Valuation: Asymchem Laboratories (Tianjin) Co., Ltd.

Market Cap 62.52B 9.31B 8.07B 7.62B 6.91B 12.96B 893B 13.05B 90.95B 35.05B 453B 34.98B 34.21B 1,440B P/E 2026 *
47.3x
P/E 2027 * 35.7x
Enterprise Value 57.85B 8.62B 7.47B 7.05B 6.39B 11.99B 826B 12.08B 84.15B 32.43B 419B 32.36B 31.65B 1,332B EV / Sales 2026 *
7.15x
EV / Sales 2027 * 6x
Free-Float
61.13%
Yield 2026 *
0.76%
Yield 2027 * 1.02%
Manager TitleAgeSince
Chief Executive Officer 70 1998-10-06
Chief Executive Officer 49 2022-01-18
President - -
Director TitleAgeSince
Director/Board Member 49 2011-07-17
Chairman 70 1998-10-06
Director/Board Member 65 2011-07-17
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 9.32B
+0.29%+1.77%+52.87%+98.69% 1,015B
-0.83%-1.83%+48.92%+63.64% 642B
+0.62%+6.03%+21.21%+73.40% 463B
-0.22%+2.88%+38.48%+37.98% 353B
-0.07%+1.82%+16.57%+23.39% 265B
-0.31%+2.02%+6.15%+10.75% 254B
-0.90%-4.03%+37.51%+44.72% 206B
-1.60%-5.51%-22.30%-58.60% 191B
+0.04%-0.81%+29.24%+92.21% 182B
Average -0.36%-3.35%+25.41%+42.91% 396.69B
Weighted average by Cap. -0.22%-2.21%+34.50%+59.38%

Financials

2026 *2027 *
Net sales 8.09B 1.2B 1.04B 985M 894M 1.68B 115B 1.69B 11.77B 4.53B 58.58B 4.53B 4.43B 186B 9.8B 1.46B 1.27B 1.19B 1.08B 2.03B 140B 2.05B 14.26B 5.49B 71B 5.48B 5.36B 226B
Net income 1.41B 210M 182M 172M 156M 293M 20.15B 295M 2.05B 791M 10.22B 790M 772M 32.5B 1.82B 271M 235M 221M 201M 377M 25.95B 379M 2.64B 1.02B 13.16B 1.02B 994M 41.85B
Net Debt -4.67B -696M -603M -569M -516M -969M -66.72B -976M -6.8B -2.62B -33.85B -2.61B -2.56B -108B -3.66B -545M -472M -445M -404M -758M -52.19B -763M -5.32B -2.05B -26.48B -2.05B -2B -84.18B
Logo Asymchem Laboratories (Tianjin) Co., Ltd.
Asymchem Laboratories Tianjin Co Ltd is a China-based company mainly engaged in providing one-stop comprehensive services for pharmaceutical outsourcing. The Company's business includes customized research and development and production of small molecule drugs (CDMO), chemical macromolecule CDMO, clinical research services, formulation CDMO, biological macromolecule CDMO, technology output and synthetic biology. The Company's product categories cover peptides, oligonucleotides, monoclonal antibodies, antibody-conjugated drugs and messenger RNA. The Company mainly conducts its business in domestic and foreign markets.
Employees
10,617
Trader
Investor
Global
Quality
ESG MSCI
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!